After two days of widespread outrage, the former hedge fund manager that bought up the rights to a more than 60-year-old drug and then raised the price has relented.
Martin Shkreli became the Internet's public enemy number one after the story emerged that his startup, Turing Pharmaceuticals, had bought up the rights to an old, generic anti-parasite drug and jacked up the price from $13.50 per pill to around $750.
[seealso slug=http://sale-online.click/2015/09/21/hedge-fund-drug-price/%5D%3C/p%3E%3Cp%3ETuesday night, Shkreli announced in an interview with ABC News that his company would be lowering the price. He did not, however, say exactly by how much.
He said it would be reduced to "to a point that is more affordable and is able to allow the company to make a profit but a very small profit."
Later on Tuesday, Shkreli also made his Twitter private. He had been using the account to defend himself and retweet supporters.
The drug, known as Daraprim, is a common anti-parasite treatment for people who suffer from depleted immune systems, such as people living with AIDS.